Recent insider activity at Recursion Pharmaceuticals consisted of 3 Tax Payment transactions by 3 insiders, totaling $437,905.65 across 111,490 shares on November 16, 2026. Average transaction value ...
REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy ...
One of the most trusted quality checks in AI-assisted biology comes from a 63-year-old protein geometry blueprint by Indian ...
Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...